Butterfly Leads the Drive on Semiconductor to Make the Most Out of Ultrasound

“It’s not just gonna be about image quality. It’s gonna be about image quality and interpretation”, Butterfly Network’s CEO Joe DeVivo explains to Bloomberg Intelligence. In this Vanguards of Healthcare podcast episode, DeVivo sits down with BI analyst Matt Henriksson for an in-depth interview to t…

Citizen Health’s Plan to Put an AI Advocate in Every Patient’s Pocket

“The number one thing that results in a better outcome for someone who is sick is actually, ‘Do you have an advocate on your side?’” says Farid Vij, co-founder and CEO of Citizen Health. Vij joins Bloomberg Intelligence analyst Jonathan Palmer to explain how Citizen Health is building an AI-powered…

Distalmotion’s Approach to Spread Surgical Robots to More

“It’s designed to be simple in a way, even though it’s an incredibly complex device”, Distalmotion CEO Greg Roche explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Roche sits down with BI analyst Matt Henriksson for an in-depth interview on the company, how its D…

Bristol Myers on Why Neuroscience Could Be the Next Oncology

“Neuroscience is what oncology was 20 years ago,” says Cristian Massacesi, Chief Medical Officer and Head of Development at Bristol Myers Squibb. Massacesi joins Bloomberg Intelligence pharmaceuticals analyst Sam Fazeli to discuss Bristol Myers’ push into neuroscience, including Alzheimer’s therapi…

Restor3D Combines AI with 3D Printing to Create Personalized Ortho Solutions

“If you plan, the cases can go much more smoothly. And if you have patient-specific instrumentation, they can go much more quickly” says restor3D’s CEO Kurt Jacobus in this episode of Vanguards of Healthcare. He sat down with BI analyst Matt Henriksson to elaborate on personalized orthopedic implan…

AstraZeneca’s ASCO Readout on Oncology’s Next Wave

“I think it’s the most exciting period in cancer discovery and development that I’ve experienced over the last 25 years,” says Susan Galbraith, executive vice president of oncology R&D at AstraZeneca. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli fresh from the ASCO conference to unpack…

Ocular Therapeutix Cuts Blindness Toll

“Forty percent of patients in this country alone in the first year drop out [of current retinal disease treatments] and every one of those patients ends up going blind. By far the most expensive disease in the world is blindness and the reason for that is really quite simple. It’s because the morta…

IRhythm Pushes a Proactive Approach to Monitoring

“We’re seeing it already to much more of a preventative proactive monitoring to find these things earlier in the patient journeys and help eliminate and prevent and reduce downstream costs,” IRhythm Technologies CEO Quentin Blackford discusses the opportunities of remote monitoring with Bloomberg I…

Pulse Biosciences Brings Differentiated Nanosecond Technology to PFA

Based on long-term results, “the effectiveness of that nanosecond pulse electric field begins to look as if it is a step function ahead of first generation PFA,”  Pulse Biosciences CEO Paul LaViolette says, referring to the next stage of pulsed-field ablation innovation. In this Vanguards of Health…

RTW’s Rod Wong on Biotech’s Revival and the Global Shift

“I think this is going to be the most eventful ASCO for biotech in a while,” says Dr. Roderick Wong, founder of RTW Investments, referring to the annual meeting of the American Society of Clinical Oncology. Wong joins Bloomberg Intelligence analyst Sam Fazeli on the Vanguards of Health Care podcast…